1 Alterations in Lipid Profiles in Children with Perinatally Acquired HIV

2 Infection living in Ghana

3

4 Ruth Ayanful-Torgby^{1,2*}, Veronika Shabanova^{1,3}, Akosua A. Essuman², Emmanuel Boafo²,

5 Linda E. Amoah², Elijah Paintsil^{1,4*}

- 6 ¹ Department of Pediatrics, Yale School of Medicine, New Haven, CT USA
- 7 ² Department of Immunology, Noguchi Memorial Institute for Medical Research, University of
- 8 Ghana, Accra, Ghana
- 9 ³ Department of Biostatistics, Yale School of Public Health, New Haven, CT USA
- ⁴ Department of Pediatrics, Boston University Chobanian & Avedisian School of Medicine,
- 11 Boston, MA USA
- 12 *Corresponding authors: <u>elijahp@bu.edu; ruthmine2@gmail.com</u>
- 13

14 Abstract

15 Children and adolescents who acquired HIV perinatally and are on lifelong antiretroviral therapy 16 (ART) are at increased risk of lipid abnormalities, premature atherosclerosis, and early onset 17 cardiovascular diseases (CVD). Majority of these children reside in sub-Saharan Africa, where 18 monitoring of lipid profiles is not routine. In this study, we assessed the age dependent prevalence 19 of dyslipidemia among children and adolescents who acquired HIV in Ghana.

20

In this cross-sectional study we examined lipid profiles of 397 children aged 6 to 18 years. Dyslipidemia was defined by elevated total cholesterol (TC) (≥200 mg/dL) or triglyceride (TG) levels (>150 mg/dL) or low-density lipoprotein cholesterol (LDL-C) (>130 mg/dL) or reduced high-density lipoprotein cholesterol (HDL-C) (<35 mg/dL). Dyslipidemia prevalence, by at least one criterion and for each criterion separately, was compared between age groups 6 - 12 (pre-teen) and 13 - 18 (teenage) years, as well as by sex.

27

28 The overall prevalence of dyslipidemia was 42.32%, and by individual criterion was 9.07% using 29 LDL-C, 11.84% using TC, 15.87% using TG, and 24.00% using HDL-C. Additionaly, 5.04% 30 (n=20) of the participants showed abnormalities across three parameters. Teenagers had a higher 31 overall prevalence of dyslipidemia (46.75% vs. 39.04%, p=0.12). Criterion-based dyslipidemia prevalence varied across age groups, with TC-based (14.04% vs. 8.88%, p=0.12) being higher in 32 33 the pre-teen group, while elevated TG-based (20.12% vs. 12.72%, p=0.05) and low levels of HDL-34 based (28.99% vs. 20.60%, p=0.05) were more prevalent in the teenagers. The mean levels of TC 35 (p=0.04) and LDL-C (p=0.03) were significantly higher in the pre-teen age groups. Females had

nearly twice as high as that of males with prevalence of abnormal LDL-C levels (11.39% vs. 6.67%,
p=0.13).

38

This study showed a high prevalence of dyslipidemia among children who acquired HIV perinatally
and are on ART, with age-related variations in lipid profiles. These findings emphasize the
importance of implementing routine monitoring for lipid disorders within this population. **Keywords:** Dyslipidemia, children living with HIV, Lipids profile

43

44 Introduction

45 Dyslipidemia, defined as increased low density lipoprotein (LDL-C), high triglycerides (TG) and 46 cholesterol (TC), and low high density lipoprotein (HDL-C), is the most common metabolic 47 disorder in individuals living with HIV, regardless of their treatment status ^{1–3}. Moreover, there are 48 reports of a significant association between dyslipidemia and the type of antiretroviral therapy 49 (ART) regimens. For instance, non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 50 protease inhibitors (PIs) are associated with low HDL-C and hypertriglyceridemia ^{4,5}. Before 51 initiation of ART, HIV infection increases triglycerides and decreases TC, HDL-C, and LDL-C⁶. 52 There are mixed reports on the trends of the various lipids after initiating ART. In a study from 53 Ethiopia, the prevalence of dyslipidemia was 70% and 58% for ART-experienced and ART-naïve 54 children, respectively 7. In this study, the frequency of individuals with low HDL-C and 55 hypertriglyceridemia were higher among children on ART, however, there were no differences in 56 total cholesterol and LDL-C⁷.

58 Dyslipidemia has been associated with a higher prevalence of cardiovascular diseases (CVD) 59 among people living with HIV (PLWH) compared to the general population. The risk of CVD 60 among PLWH is twice as high as those in the general population^{8,9}, primarily attributed to 61 dyslipidemia. Moreover, CVD including conditions like myocardial infarction, manifests among PLWH a decade or two earlier than in the general population ¹⁰. This trend is particularly significant 62 63 in sub-Saharan Africa, where HIV prevalence is high ¹¹. There is a paucity of studies on CVD in 64 children living with HIV, although they are susceptible to cardiovascular complications due to 65 dyslipidemia¹². In a study of Ugandan children and adolescents living with HIV aged 1 to 17 years. 66 the prevalence of dyslipidemia was 74%; of those with dyslipidemia, 56% had low HDL-C, 22% 67 had hypertriglyceridemia, 16% had high LDL-C, and 11% had high total cholesterol levels ¹⁹⁰. 68 Elevated LDL-C and low HDL-C in children and young adults have been attributed to abnormalities 69 in the arterial aorta ¹³, which serve as precursor to atherosclerosis ¹⁴. Additionally, low HDL-C 70 levels are associated with inflammation, contributing to insulin resistance and other 71 cardiometabolic disorders, including metabolic syndrome. Despite the established link between 72 dyslipidemia and CVD, lipid profiles are not routinely monitored in children living with HIV, 73 potentially hindering early detection and intervention effort. Considering that alteration in lipid 74 metabolism is associated with cardiometabolic diseases, an emerging public health problem in most 75 developing countries, including Ghana, it is imperative to detect precursors of these diseases, such 76 as dyslipidemia. Early detection of dyslipidemia can help avert related pathologies, such as 77 myocardial infarction and type 2 diabetes, which are on the rise in young adults living with HIV.

78

Taken together, dyslipidemia in children living with HIV is an emerging public health concern as
continued lipid abnrmalities may contribute to the development of atherosclerosis and other CVD

81 in early adulthood. Given the significant HIV burden in sub-Saharan Africa, a large proportion of 82 children living with the virus in this region may be at risk of developing CVD associated with 83 dyslipidemia, which could go unnoticed due to insufficient screening. To address this gap, our study 84 aimed to assess the prevalence of dyslipidemia and its association with age and sex among 85 perinatally HIV-infected children receiving ART in Ghana.

- 86
- 87 Methods
- 88 Study Participants

This multi-center cross-sectional study was conducted from 5th January to 28th June 2022 among 89 90 children and adolescents living with perinatally acquired HIV, aged 6 to 18 years from study 91 participants were recruited from ten pediatric antiretroviral treatment clinics in ten facilities in 92 Greater Accra and Eastern regions of Ghana. Details of the study participants have been published 93 previously ¹⁵. In brief, the study recruited 400 participants from ten pediatric ART treatment clinics 94 across ten health facilities in Greater Accra and Eastern Regions of Ghana, which share similar 95 socioeconomic indices. All participants acquired HIV pernatally and had been on uninterrupted 96 antiretroviral therapy for at least a year, adhering to the national ART treatment guidelines for 97 children and adolescents. These guidelines prioritize first-line, second-line, or third-line regimens 98 with appropriate dosages based on ART class and age. We excluded all individuals with viral 99 hepatitis and TB due to potential interference with lipid/glucose metabolism caused by alternative 100 medications and regimens ¹⁶. All individuals who were clinically stable and willing to participate 101 were recruited after being briefed on the study's objectives and procedures. Age-appropriate written 102 parental informed consent, assent, and consent were obtained prior to participants' enrollment,

followed by scheduled sampling procedure (blood draw and urine collection), questionnaire
 administration and anthropometric measurements taken at the clinics.

105

106 Ethical Approvals

107 The study protocol was reviewed and approved by the Institutional Review Boards of the Ghana 108 Health Service (Protocol # GHS-ERC: 025/09/21) and the Noguchi Memorial Institute for Medical 109 Research, University of Ghana (Protocol # CPN 015/21-22). Written parental informed consent was 110 obtained for children aged 6-12 years, while both parental consent and assent were obtained for 111 participants aged 12–17 years. For participants aged 18 years, individual consent was obtained. All 112 participants were assured of anonymity and data protection. Research data was stored and used in 113 compliance with the ethical guidelines approved for the study, ensuring participant protection as 114 previously reported ¹⁵.

115

116 Data Collection

Detailed information on data collection methods has been published previously ¹⁵. In brief, we administered questionnaires to participants or their parents/guardians to collect demographic (age, sex, and residental location), educational (participants' education), and socioeconomic information (parent or guadran educational level and occupation). Additionally, anthropometric measurements (upper arm circumference, waist circumference, hip circumference, and neck circumference) were conducted by a trained member of the study team or health staff.

123

124 **Biochemical Parameters**

125 All participants provided 2.5 ml blood samples after an overnight fasting period, before the next

morning's blood collection. Serum was separated from 2 mL whole blood samples collected in gel
tubes for subsequent analysis of lipid profile and the remaining 0.5 mL blood used for other
laboratory investigations. The levels of TG, HDL-C, and total TC were measured using a chemical
analyzer (Mindray BS-240, China). LDL-C levels were determined by the Friedewald formula ¹⁷. **Definitions of Variables**The primary outcome of interest was dyslipidemia, defined as presence of any of the following
parameters: by elevated TC (≥200 mg/dL), TG (≥150 mg/dL), or LDL-C (≥130 mg/dL), or reduced

134 levels of HDL-C (\leq 35 mg/dL) ¹⁸. Age was stratified into two categorized as 6 - 12 years (pre-teen)

and 13 - 18 years (teenage), while sex was categorized as female or male, based on gender assignedat birth.

137

138 Statistical Analysis

139 Categorical variables such as sex, educational level, and caregiver type are summarized as count 140 (n) and percentage (%), while numeric variables such as age were expressed as means and standard 141 deviations (SD). Participant characteristics were compared between the two age groups using 142 Student's t-test or Chi-square statistics for continuous and categorical variables, respectively. We 143 estimated the prevalence of dyslipidemia, defined as having at least one abnormal parameter, as 144 well separately based on each of the four lipid parameters (TC, TG, LDL-C, HDL-C), and compared 145 them based on age group (pre-teen vs. teenage) and sex (male vs. female) using two-samples z-test, 146 summarizing as counts and percentage. Since we did not power our statistical analysis a priori, we 147 did not rely solely on the strict two-sided alpha level of 0.05 to make conclusions, but coupled our 148 interpretations with the magnitude of the observed effect sizes. For example, a difference of at least

149	5% in the prevalence of dyslipidimia or a relative difference of at least 1.5 (e.g., the prevalence in
150	one group divided by the prevalence in a comparison group), was considered clinically meaningful.
151	All statistical analyses were performed using R (version 4.2.2) and GraphPad Prism (version 9.01).

152

153 **Results**

154 Characteristics of Study Participants

155 The analysis included 397 of 400 participants with complete lipid profile data on four key lipid

parameters, i.e., TC, TG, LDL-C, and HDL-C. Participants in the pre-teen age group (6 - 12 years)

157 represented 57.43% of the study participants. Distribution of sex variable was similar in the two

age groups. Variations in BMI measures were evident across the age groups (p < 0.0001), with the

159 pre-teen group with a mean BMI of 15.65 (SD=3.07) compared to 17.58 (SD=3.48) among the

160 teenage group. The mean BMI Z-score values also differed (p<0.0001), with the pre-teen group

161 showing a mean negative score of -0.48 (SD=0.66), while the teenage group demonstrated a mean

- 162 positive score of 0.65 (SD=1.02) (**Table 1**).
- 163

164 **Table 1** Characteristics of Study Participants

		Age gi	roups
Variable	Total (N=397)	Pre-teen (n=228)	Teenage (n=169)
Age, year, Mean (SD)	11.57 (3.49)	9.66 (2.51)	16.94 (3.85)
BMI Mean (SD)	16.94 (3.85)	15.65 (3.07)	17.58 (3.48)
BMI Z-score Mean (SD)	0.00 (0.71)	-0.48 (0.66)	0.65 (1.02)
WHR Mean (SD)	0.83 (0.08)	0.86 (0.07)	0.80 (0.07)
Sex, n (%)			· · · ·
Female	202 (50.88)	117 (51.32)	85 (50.30)
Education, n (%)			
Basic	354 (89.17)	227 (99.56)	127 (75.15)
Secondary	41 (10.33)	1 (0.44)	40 (23.67)
None	2 (0.50)	0 (0.00)	2 (1.18)
Guardian, n (%)			
Parent	305 (76.83)	181 (79.39)	124 (73.37)
Sibling	12 (3.02)	3 (1.32)	9 (5.34)
Grandparent	31 (7.81)	15 (6.58)	16 (11.24)

Other relative	25 (6.30)	13 (5.70)	12 (7.10)
^a Others	24 (6.05)	16 (7.02)	8 (4.73)

¹⁶⁶ ^aSelf or non-relative including living in orphanage Abbreviations: SD=standard deviation, BMI=Body Mass

167 Index, WHR=Waist-Height Ratio

168

169 Prevalence of Dyslipidemia among the Study Participants

170 One hundred and sixty eight participants had dyslipidemia, representing an overall prevalence of 171 42.32% in the study participants. Categorization of dyslipidemia based on the frequency of altered 172 levels among the four lipid parameters showed that the majority of participants (n=114, 28.72%) 173 had altered levels in only one lipid parameter. Thirty-four individuals (8.56%) showed 174 abnormalities in two parameters, while a smaller subset of 20 individuals (5.04%) had abnormalities 175 in three parameters. No individual showed dyslipidemia characterized by abnormalities in all four 176 lipid parameters. Compared to pre-teens, teenagers had higher prevalence of at least one altered 177 parameter of dyslipidemia (46.75% vs. 39.04%, p=0.12; **Table 2**). The prevalence of dyslipidemia 178 and the number of altered lipid parameters did not differ between males and females, with the 179 exception of proportion of females with abnormal LDL-C levels being nearly twice as high as that 180 of males (11.39% vs. 6.67%, p=0.13; Supplementary Tables S1 and S2).

181

182 **Table 2** Comparison Frequency of Altered Lipid Parameters between Age Groups/Sex

	Age group			
Altered parameters	Total (n, %)	Pre-teen (n, %)	Teenage (n, %)	p-value
At least 1 (≥1)	168 (42.32)	89 (39.04)	79 (46.75)	0.12
1	114 (28.72)	61 (26.75)	53 (31.40)	0.08
2	34 (8.56)	14 (6.14)	20 (11.80)	
3	20 (5.04)	14 (6.14)	6 (3.60)	
Dyslipidemia (sex)				
Female	83 (41.09)			0.61
Male	85 (43.34)			

Age-Related Disparities in Lipid Profiles 185

186	When comparing lipid profiles across age groups (Table 3), the teenage group showed -higher mean
187	TG levels compared to the pre-teen group (p=0.15). LDL-C (p=0.03) and TC (p=0.04) levels were
188	lower in the older (teen) age group compared to the younger population. However, the mean HDL-C
189	levels between the two age brackets were similar (p=0.28). The prevalence of elevated TG was
190	higher in the teenage group (p=0.05). The prevalence of elevated TC was nearly double in the
191	younger age group compared to the older age group (p=0.12). Dyslipidemia prevalence based on
192	LDL-C was similar in the two age groups (p=0.41). Additionally, the number of individuals with
193	low levels of HDL-C was higher in the teenagers than in the pre-teen group (p=0.05).

194

195 Table 3 Lipid Profile and Comparison Across Age Groups

196

Damanatan	Total (N-207)	Age Group		
Parameter	Total (N=397)	Pre-teen (n=228)	Teenage (n=169)	p-value
Mean levels (SD) ^b				
TC (mg/dL)	156.07 (45.19)	160.11 (47.09)	150.61 (42.02)	0.04
TG (mg/dL)	96.88 (56.17)	93.37 (53.53)	101.62 (59.50)	0.15
LDL-C (mg/dL)	66.98 (52.15)	71.87 (52.19)	60.39 (51.52)	0.03
HDL-C (mg/dL)	45.05 (16.00)	45.81 (15.26)	44.03 (16.93)	0.28
Dyslipidemia, n (%	(0) ^c			
TC (mg/dL)	47 (11.84)	32 (14.04)	15 (8.88)	0.12
TG (mg/dL)	63 (15.87)	29 (12.72)	34 (20.12)	0.05
LDL-C (mg/dL)	36 (9.07)	23 (10.09)	13 (7.69)	0.41
HDL-C (mg/dL)	96 (24.18)	47 (20.61)	49 (28.99)	0.05

197 198 199 ^bp-values using Student's t-test, ^c p-values using two-sample z-test. Abbreviation: low density lipoprotein (LDL-C),

high triglycerides (TG), cholesterol (TC), low high density lipoprotein (HDL-C)

200 Discussion

201 A concerning increasing trend in the cluster of metabolic disorder components, including 202 dyslipidemia, has been noted among children living with HIV, predisposing them to an increased 203 risk to cardiovascular disease ¹⁹. In this study, we examined alterations in four lipid profile 204 parameters: elevated levels of TC, TG, LDL-C, and low levels of HDL-C, all of which are 205 acknowledged as significant contributors to CVD risk. Our findings revealed an overall 206 dyslipidemia prevalence of 42.32% within our study participants, with the prevalences of individual 207 parameters being 9.07% for LDL-C, 11.84% for TC, 15.87% for TG, and 24.18% for HDL-C. We 208 observed that compared to the preteens in our study, teenage participants had higher prevalence of 209 dyslipidemia primarily driven by the elevation in TG and depression in HDL-C. Dyslipidemia 210 among the pre-teens was characterisized by elevated TC. The prevalence of dyslipidemia or levels 211 of any of the four lipid parameters were not affected by being biologically male or female.

212

213 The prevalence of dyslipidemia in our study was high, however, a study conducted among South 214 African children and adolescents living with HIV reported an even higher prevalence of 74%²⁰. In 215 our study cohort, alterations in specific lipid parameters included 9% for elevated LDL-C, 12% for 216 elevated total cholesterol (TC), 16% for elevated triglycerides (TG), and 24% for low HDL-C; this 217 is consistent with trends observed in other African studies $^{21-23}$. Among the four lipid parameters 218 measured, the prevalence of low HDL-C levels was the highest, followed by hypertriglyceridemia. 219 It is well established that low HDL-C and hypertriglyceridemia are the predominant components of 220 dyslipidemia in children living with HIV, with prevalence rates in sub-Saharan Africa ranging from 221 0% to 29% for hypertriglyceridemia ^{24,25}, and 5% to 72% for low HDL-C ^{22,25,26}. Similar findings 222 have been reported in studies of adults living with HIV in Africa²⁷, although the prevalence in

223 children tends to be lower, ranging from 6% to 9% for hypertriglyceridemia and 6% to 47% for low 224 HDL-C^{21–23,28}. Notably, a recent study in children living with HIV in Ethiopian reported a much 225 higher prevalence of 72% for low HDL-C²⁶. Outside of Africa, higher rates of low HDL-C have 226 also been observed among individuals living with HIV in Asian populations. For example, a recent 227 study found that 47% of Thai youth aged 15 to 24 years had low HDL-C levels, while a study from 228 India reported that 83% of ART naïve children living with HIV aged 2 to 12 years had low HDL-229 C^{29,30}. In our study, sex did not significantly influence lipid levels or the prevalence of dyslipidemia, 230 except for LDL-C, which was more prevalent in females. Our finding is consistent with previous 231 findings that females usually have higher LDL-C levels than males at puberty³¹. Our results are 232 consistent with previous research examining dyslipidemia by sex in children living with HIV^{32} . 233 However, in the general population with respect to age or sex, lipid profiles have varied across 234 studies and populations, particularly when factors such as obesity is considered 33,34 .

235

236 We observed differences in TG, LDL-C, and TC levels between different age groups. Dyslipidemia 237 prevalence varied across age groups, with most individuals showing abnormalities in only one 238 parameter. The younger age group showed much higher levels of the lipid parameters (TC and 239 LDL-C) than the older group as previously reported eventhough there are conflicting reports based 240 on the population being studied ^{35,36}. This difference could be attributed to confounding factors such 241 as nutrition, viral load, or immune parameters, which were not measured in this study. While the 242 prevalence of dyslipidemia was high across both age groups, teenagers were more likely to have 243 altered levels of TG which is consistent with previous studies suggesting an increase in the 244 prevalence of dyslipidemia during adolescence, possibly attributed to hormonal changes, or 245 prolonged exposure to HIV and its treatments ^{3,37}.

246

247 In terms of the frequency of dyslipidemia based on number of alterations in the four lipid parameters. 248 we observed that the majority of participants showed abnormalities in just one lipid parameter as 249 reported in other studies. However, close to 14% of our study participants showed alterations in 250 two or three parameters concurrently. Understanding this variability and the extent of multiple 251 markers of dyslipidemia is crucial for tailored interventional strategies, as different lipid 252 abnormalities may confer varying cardiovascular risks. The presence of multiple-markers of 253 dyslipidemia may not only increase the risk but also predispose individuals to coronary heart 254 disease ^{38,39}. Several studies have reported that disruptions in multiple lipid parameters significantly 255 elevate CVD risk, with others citing the presence of low HDL-C levels as a key determinant 41,42. 256 Low HDL-C level is a crucial determinant of cardiovascular risk because HDL-C plays a pivotal 257 role in cholesterol metabolism, inflammation regulation, endothelial function, and the prevention 258 of atherosclerosis. Therefore, the prevalence of dyslipidemia, particularly low HDL-C, warrants 259 routine monitoring of lipid profile in children living with HIV curb CVD sequelae in their adulthood. 260

Although our study provided valuable insights on dyslipidemia in children living with HIV in Ghana, there were limitations that need to be acknowledged. First, missing variables of HIV diseases status such as treatment history, ART regimen, viral load, and CD4 count. Second, the cross-sectional design and lack of HIV-specific factors could introduce bias and influence dyslipidemia prevalence estimates and other risk factors, as previously acknowledged ¹⁵. Third, the study design limits the ability to draw causal inferences. Furture longitudinal studies are needed to validate our findings.

In conclusion, our results show a high prevalence of dyslipidemia among perinatally children living with in Ghana. Low HDL-C levels, a pivotal predictor of CVD risk and inflammation, was the prevalent parameter among individuals with dyslipidemia in our study. This highlights the need for routine monitoring of lipid profile of children living with HIV and proactive management to prevent CVDs in adulthood. Furthermore, there is urgent need for further research into the etiopathogenesis of rising dyslipidemia and evolving epidemic of cardiometabolic diseases in children living with HIV, particularly in sub-Saharan Africa.

276

277 Author Contributions

Conceived and designed the experiments: RAT, EP. Data Collection: RAT, AAY, EB. Performed
the experiments: RAT, AAY, EB. Analyzed the data: RAT. Original Draft: RAT. Reviewed
manuscript drafts: RAT, VS, LEA, EP.

281

282 Acknowledgements

We thank the study participants, their parents or guardians, ART clinic staff, and the Ghana National AIDS Control Program for their cooperation and support. This study received support from the Fogarty International Center and the National Institute of Alcohol Abuse and Alcoholism (NIH D43 TW011526).

287

288 Conflicts of Interest

289 The authors declare no conflicts of interest.

291 **Reference**

- 292 1. the PREDICT study group et al. High Prevalence of Lipid Abnormalities among Antiretroviral-
- 293 Naive HIV-Infected Asian Children with Mild-To-Moderate Immunosuppression. *Antivir. Ther.*
- **16**, 1351–1355 (2011).
- Chantry, C. J. *et al.* Lipid and Glucose Alterations in HIV-Infected Children Beginning or
 Changing Antiretroviral Therapy. *Pediatrics* 122, e129–e138 (2008).
- Trevillyan, J. M. *et al.* Changes in plasma lipidome following initiation of antiretroviral therapy.
 PLOS ONE 13, e0202944 (2018).
- 4. Ishaya, A. & Olukemi, I. Prevalence of metabolic syndrome in HIV-infected and Non-HIV
 infected Nigerian children in Jos. *J. Med. Trop.* 22, 8 (2020).
- 301 5. McComsey, G. A. *et al.* Increased carotid intima media thickness and cardiac biomarkers in
 302 HIV infected children. *AIDS* 21, 921–927 (2007).
- 303 6. Sprinz, E., Lazzaretti, R. K., Kuhmmer, R. & Ribeiro, J. P. Dyslipidemia in HIV-infected
 304 individuals. *Braz. J. Infect. Dis.* 14, 575–588 (2010).
- 305 7. Tadesse, F. G. et al. The Relative Contribution of Symptomatic and Asymptomatic Plasmodium
- 306 vivax and Plasmodium falciparum Infections to the Infectious Reservoir in a Low-Endemic
- 307 Setting in Ethiopia. *Clin. Infect. Dis.* **66**, 1883–1891 (2018).
- Shah, A. S. V. *et al.* Global Burden of Atherosclerotic Cardiovascular Disease in People Living
 With HIV: Systematic Review and Meta-Analysis. *Circulation* 138, 1100–1112 (2018).
- 310 9. Alonso, A. *et al.* HIV Infection and Incidence of Cardiovascular Diseases: An Analysis of a
 311 Large Healthcare Database. *J. Am. Heart Assoc.* 8, e012241 (2019).
- 312 10. Freiberg, M. S. et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern.
- 313 *Med.* **173**, 614–622 (2013).

- 314 11. Shah, A. S. V. et al. Global Burden of Atherosclerotic Cardiovascular Disease in People Living
- 315 With HIV: Systematic Review and Meta-Analysis. *Circulation* **138**, 1100–1112 (2018).
- 316 12. Boccara, F. et al. HIV and Coronary Heart Disease. J. Am. Coll. Cardiol. 61, 511–523 (2013).
- 317 13. Sainz, T. et al. Cardiac Function in Vertically HIV-infected Children and Adolescents in the
- 318 Era of Highly Active Antiretroviral Therapy. *Pediatr. Infect. Dis. J.* **34**, e125–e131 (2015).
- 319 14. Hao, W. & Friedman, A. The LDL-HDL Profile Determines the Risk of Atherosclerosis: A
 320 Mathematical Model. *PLoS ONE* 9, e90497 (2014).
- 321 15. Ayanful-Torgby, R. *et al.* High prevalence of impaired glucose metabolism among children and
 322 adolescents living with HIV in Ghana. *HIV Med.* hiv.13614 (2024) doi:10.1111/hiv.13614.
- 323 16. National AIDS/STI Control Programme, Ghana Health Service. Consolidated Guidelines for
- HIV Care in Ghana Test, Treat & Track. (2019).
- 325 17. Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the Concentration of Low326 Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge.
- 327 *Clin. Chem.* **18**, 499–502 (1972).
- 18. Kavey, R.-E. W. *et al.* American Heart Association guidelines for primary prevention of
 atherosclerotic cardiovascular disease beginning in childhood. *Circulation* 107, 1562–1566
 (2003).
- 19. Kelesidis, T. & Currier, J. S. Dyslipidemia and Cardiovascular Risk in Human
 Immunodeficiency Virus Infection. *Endocrinol. Metab. Clin. North Am.* 43, 665–684 (2014).
- 333 20. Nampijja, D. Dyslipidemia and its Correlates among HIV Infected Children on HAART
- 334 Attending Mbarara Regional Referral Hospital. Int. Clin. Pathol. J. 4, (2017).

- 335 21. Musiime, V. et al. Anthropometric Measurements and Lipid Profiles to Detect Early
- 336 Lipodystrophy in Antiretroviral Therapy Experienced HIV-Infected Children in the Chapas-3
- 337 Trial. Antivir. Ther. 19, 269–276 (2014).
- 338 22. Arpadi, S. et al. Metabolic abnormalities and body composition of HIV-infected children on
- 339 Lopinavir or Nevirapine-based antiretroviral therapy. Arch. Dis. Child. 98, 258–264 (2013).
- 340 23. Innes, S., Abdullah, K. L., Haubrich, R., Cotton, M. F. & Browne, S. H. High Prevalence of
- 341 Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on
 342 Antiretroviral Therapy. *Pediatr. Infect. Dis. J.* 35, e1–e7 (2016).
- 343 24. Piloya, T., Bakeera-Kitaka, S., Kekitiinwa, A. & Kamya, M. R. Lipodystrophy among HIV-
- infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross
 sectional study. J. Int. AIDS Soc. 15, (2012).
- 346 25. Bwakura-Dangarembizi, M. et al. Prevalence of Lipodystrophy and Metabolic Abnormalities
- 347 in HIV-infected African Children after 3 Years on First-line Antiretroviral Therapy. *Pediatr.*
- 348 Infect. Dis. J. **34**, e23–e31 (2015).
- 349 26. Ambisa Lamesa, T. et al. Dyslipidemia and Nutritional Status of HIV-Infected Children and
- 350 Adolescents on Antiretroviral Treatment at the Comprehensive Chronic Care and Training
- 351 Center of Jimma Medical Center. *HIVAIDS Auckl. NZ* **15**, 537–547 (2023).
- 352 27. Naidu, S., Ponnampalvanar, S., Kamaruzzaman, S. B. & Kamarulzaman, A. Prevalence of
- 353 Metabolic Syndrome Among People Living with HIV in Developing Countries: A Systematic
- 354 Review. *AIDS Patient Care STDs* **31**, 1–13 (2017).
- 355 28. Kisitu, G. et al. High prevalence of low high-density lipoprotein cholesterol and insulin
- 356 resistance among children and adolescents living with HIV in Uganda: harbinger for metabolic
- 357 syndrome? *HIV Med.* **25**, 262–275 (2024).

- 358 29. Aurpibul, L., Namwongprom, S., Sudjaritruk, T. & Ounjaijean, S. Metabolic syndrome,
- biochemical markers, and body composition in youth living with perinatal HIV infection on
 antiretroviral treatment. *PLOS ONE* 15, e0230707 (2020).
- 361 30. Padmapriyadarsini, C. et al. High Prevalence of Lipid Abnormalities and Insulin Resistance
- 362 Among Antiretroviral Naïve HIV-infected Children in India. *Pediatr. Infect. Dis. J.* 37, 253–
 363 257 (2018).
- 364 31. Dobashi, K. Changes in Serum Cholesterol in Childhood and its Tracking to Adulthood. J.
 365 *Atheroscler. Thromb.* 29, 5–7 (2022).
- 366 32. Alves Junior, C. A. S. et al. Association between lipid and glycemic profile and total body and
- trunk fat in children and adolescents diagnosed with HIV+. *Clin. Nutr. ESPEN* **53**, 7–12 (2023).
- 368 33. Baig, Z. A. *et al.* Risk Analysis and Assessment of Lipid Abnormalities as the Earliest
 369 Complication in Newly Diagnosed Diabetic and Non-Diabetic Individuals of a Local
 370 Population. *Healthcare* 10, 2308 (2022).
- 34. Huang, Y. *et al.* Lipid profiling identifies modifiable signatures of cardiometabolic risk in
 children and adolescents with obesity. *Nat. Med.* (2024) doi:10.1038/s41591-024-03279-x.
- 373 35. Webber, L. S., Srinivasan, S. R., Wattigney, W. A. & Berenson, G. S. Tracking of Serum Lipids
 374 and Lipoproteins from Childhood to Adulthood. *Am. J. Epidemiol.* 133, 884–899 (1991).
- 375 36. EXPERT PANEL ON INTEGRATED GUIDELINES FOR CARDIOVASCULAR HEALTH
- 376 AND RISK REDUCTION IN CHILDREN AND ADOLESCENTS. Expert Panel on Integrated
- 377 Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents:
- 378 Summary Report. *Pediatrics* **128**, S213–S256 (2011).
- 379 37. Schienkiewitz, A. et al. Age, maturation and serum lipid parameters: findings from the German
- 380 Health Survey for Children and Adolescents. *BMC Public Health* **19**, 1627 (2019).

- 38. Asghari, S. *et al.* Single and mixed dyslipidaemia in Canadian primary care settings: findings
- from the Canadian primary care sentinel surveillance network database. *BMJ Open* 5, e007954
 (2015).
- 384 39. Achila, O. O. et al. A community based cross sectional study on the prevalence of dyslipidemias
- and 10 years cardiovascular risk scores in adults in Asmara, Eritrea. Sci. Rep. 12, 5567 (2022).
- 386 40. Bartlett, J. et al. Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular
- 387 Disease Risk Factor? New Insights From the Framingham Offspring Study. *Circ. Cardiovasc.*
- 388 *Qual. Outcomes* **9**, 206–212 (2016).
- 41. März, W. *et al.* HDL cholesterol: reappraisal of its clinical relevance. *Clin. Res. Cardiol.* 106,
 663–675 (2017).
- 42. Magnoni, M. *et al.* Predictive value of HDL function in patients with coronary artery disease:
 relationship with coronary plaque characteristics and clinical events. *Ann. Med.* 54, 1036–1046
- 393 (2022).
- 394